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Abstract
Yersinia pestis is the etiologic agent of plague that has killed more than 200 million people throughout the recorded history
of mankind. Antibiotics may provide little immediate relief to patients who have a high bacteremia or to patients infected
with an antibiotic resistant strain of plague. Two virulent factors of Y. pestis are the capsid F1 protein and the low-calcium
response (Lcr) V-protein or V-antigen that have been proven to be the targets for both active and passive immunization.
There are mouse monoclonal antibodies (mAbs) against the F1- and V-antigens that can passively protect mice in a murine
model of plague; however, there are no anti-Yersinia pestis monoclonal antibodies available for prophylactic or therapeutic
treatment in humans. We identified one anti-F1-specific human mAb (m252) and two anti-V-specific human mAb (m253,
m254) by panning a naı ¨ve phage-displayed Fab library against the F1- and V-antigens. The Fabs were converted to IgG1s
and their binding and protective activities were evaluated. M252 bound weakly to peptides located at the F1 N-terminus
where a protective mouse anti-F1 mAb also binds. M253 bound strongly to a V-antigen peptide indicating a linear epitope;
m254 did not bind to any peptide from a panel of 53 peptides suggesting that its epitope may be conformational. M252
showed better protection than m253 and m254 against a Y, pestis challenge in a plague mouse model. A synergistic effect
was observed when the three antibodies were combined. Incomplete to complete protection was achieved when m252 was
given at different times post-challenge. These antibodies can be further studied to determine their potential as therapeutics
or prophylactics in Y. pestis infection in humans.
Citation: Xiao X, Zhu Z, Dankmeyer JL, Wormald MM, Fast RL, et al. (2010) Human Anti-Plague Monoclonal Antibodies Protect Mice from Yersinia pestis in a
Bubonic Plague Model. PLoS ONE 5(10): e13047. doi:10.1371/journal.pone.0013047
Editor: Paulo Lee Ho, Instituto Butantan, Brazil
Received June 9, 2010; Accepted August 23, 2010; Published October 13, 2010
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public
domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: This project was supported by the Intramural Research Program of the National Institutes of Health (NIH), National Cancer Institute, Center for Cancer
Research, by federal funds from the National Cancer Institute, NIH, under contract N01-CO-12400, by the National Institute of Allergy and Infectious Diseases
Biodefense Program to Dimiter S. Dimitrov and agency Joint Science and Technology Office Defense Threat Reduction Agency (JUSTO/DTRA) proposal
no. 1.1A0018_07_RD_B to Kei Amemiya. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript. SAIC-Frederick, Inc., as one of the funders of this study, had no role in study design, data collection and analysis, decision to publish, or preparation of
the manuscript.
Competing Interests: SAIC-Fredereick, Inc. is a wholly owned subsidiary of Science Applications International Corporation and operates exclusively under a
single, long-term contract to the National Cancer Institute, part of the U.S. National Institutes of Health. All funding is derived from the U.S. Government. This does
not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
* E-mail: dimiter.dimitrov@nih.gov (DSD); kei.amemiya@us.army.mil (KA)
¤ Current address: Medimmune, LLC, Gaithersburg, Maryland, United States of America
Introduction
Yersinia pestis (Y. pestis) is the causative agent of plague that has
killed over an estimated 200 million people in previous pandemics
[1]. The current incidence of plague is low but the animal
reservoirs for Y. pestis exist worldwide. Sporadic cases have been
reported recently with an average case number of 2,500 worldwide
[2]. Y. pestis can be rendered airborne and its potential use as a
bioweapon is recognized [3] as a category A agent on the NIAID
list of biodefense-related pathogens. Current treatment for plague
consists of antibiotics, while a live attenuated vaccine against
plague is used in the former Soviet Union for prevention [4].
Nevertheless, these live attenuated whole-cell vaccines or killed
whole-cell vaccines have adverse effects to varying degrees [4].
Though both types of treatment are efficacious, there is a need for
an alternative treatment for plague [5].
A multiple-antibiotic-resistant isolate of Y. pestis has been
isolated, and drug resistance was shown to be mediated by a
self-transferable plasmid [6,7]. A subunit vaccine, which consists of
two virulent factors, the F1 protein and V-antigen, is currently in
human clinical trials [8–10]. Studies involving the vaccine antigens
in various formats have provided the proof-of-concept data that
humoral response can be efficient in protection against Y. pestis
[11,12]. There are multiple reports that mouse anti-plague
monoclonal antibodies (mAbs) against a Y. pestis challenge can
passively protect a mouse against plague [13–15]. Therefore, mAb
therapy may be an attractive alternative to the existing treatments
for plague. Despite the promising possibilities, there remains a
major hurdle in the treatment against plague and that is the
possible immune response of humans to the mouse mAbs that are
currently available. One possibility to ameliorate the immune
response against the mouse mAb is to humanize the mAb for use
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human anti-plague monoclonal antibodies for clinical usage [16].
We describe here the isolation of three mAbs from a large naive
human phage-displayed Fab library. One, designated as m252, is
against the F1- antigen and the other two (m253, m254) are
against the V-antigen. When used alone, m252 displayed good
protective effects, whereas m253 and m254 did not. However, a
clear synergistic effect was found when they were used together.
Maximum protection by m252 alone could be achieved by altering
the antibody administration schedule. This is the first report
describing the isolation of fully human anti-plague mAbs that show
efficacy in a mouse model of plague. These antibodies represent a
significant breakthrough toward possible adjunctive therapeutic
treatment of Y. pestis infection in humans.
Results
Selection and purification of human anti-F1 and anti-V
Fabs
With the F1 antigen, only the plate format yielded positive Fab
clones after four rounds of selection with the F1 antigen.
Sequencing of the clones confirmed that they were identical and
designated as m252. With the V-antigen, the plate and bead
format each yielded two positive Fab clones after four rounds of
selection with each format. One clone from each format,
designated as m253 and m254, respectively, was selected for
further analysis. Sequence analysis revealed that m252 has heavy
and light chains originated from germlines IGHV1-2*02 and
IGKV1-16*01 respectively. M253 originated from IGHV1-18*01
and IGKV1-9*01, while m254 was from IGHV3-43*01 and
IGKV1-27*01. The mutational rate ranged from zero to less than
10%. This is typical for antibodies isolated from naı ¨ve human
libraries by panning against viruses causing acute infection in
contrast to neutralizing antibodies selected from immune human
libraries by panning against HIV-1, which causes a chronic
infection [17]. Each of the clones was then transformed into
HB2152 cells and the respective Fab was expressed and purified
(Figure 1a). After conversion to IgG1 expressing clones, the three
antibody clones were transiently transfected into Freestyle HEK
293F cells, and the expressed IgG1s were purified (Figure 1c).
Binding of the selected mAbs as Fabs and IgG1s to their
antigens
To determine both the specificity and affinity of the selected
antibodies, ELISA with both Fab and IgG formats were conducted
as described in the methods. All Fabs and IgGs bound to their
respective antigens specifically without cross-reaction to other
antigens tested (Figure 1b and d). Anti-F1 Fab and IgG have
apparent affinities in the low and sub-nM range, respectively. Both
m253 and m254 Fabs have apparent affinities of approximately
100 nM (Figure 1b and d). Their IgGs however have sub-nM
apparent affinities (avidities). The avidity effect is very pronounced
for all three antibodies.
Low level of competition between the human anti-F1
and anti-V Fabs and mouse anti-F1 and anti-V mAbs
The three human anti-plague Fabs were used in competition-
ELISAs against a panel of mouse anti-plague mAbs. The mouse
anti-plague mAbs included the anti-F1 mAb F1-04-A-G1, and five
anti-V mAbs, which included the anti-V mAb 7.3 m that was
highly protective. We found no apparent competition between the
human anti-V m253 Fab and the mouse anti-V mAbs (Figure 2a).
However, we observed some weak competition between the
human anti-V m254 Fab antibody and some of the mouse anti-V
mAbs (7.3 m, 10–1 m, and 74–1 m) that we did not see with the
human anti-V m253 Fab antibody (Figure 2b). The competition
between the human anti-F1 m252 Fab antibody and the mouse
anti-F1 mAb was also minimal (Figure 2c). We ran two controls in
the competition studies with the human and mouse mAbs. For one
control we did not add a primary antibody (labeled NC, Figure 2a–
2c), and for a second control we used a nonspecific mouse isotype
IgG1 mAb in the competition assay (labeled Bm, for a Burkholderia
mallei IgG1 mAb). There was also a lack of competition between
the human anti-V m253 and m254 Fab antibodies, suggesting that
these two human anti-V Fabs recognize different epitopes (one
which may be conformational) on the V-antigen (Figure 2d). Of
note, however, is that when the competition-ELISA was
performed in a different fashion, namely when the human anti-
F1 or anti-V mAbs were allowed to bind to the respective antigens
before adding the mouse anti-F1 or anti-V mAbs, moderate
competition was detected between the human anti-F1 m252 and
the mouse anti-F1 mAbs, as well as between the human anti-V
m253 and mouse anti-V 84-1 mAbs (data not shown).
Epitope mapping by peptide-ELISA
To characterize the binding of the human anti-F1 and anti-V
mAbs to the F1- and V-antigens, respectively, more closely, we
examined the binding of the human mAbs to two separate panels
of overlapping peptides. One panel covered the full-length of the
F1 antigen (27 peptides) and the other - the V antigen (53
peptides). For the human anti-F1 m252 mAb, there was a weak-
moderate binding signal with peptides 1 and 2, which are located
at the N-terminus of the F1-antigen (Figure 3a). This suggests that
the m252 mAb may also recognize a conformational region that
involves peptides 1 and 2. The binding by human anti-V m253
mAb resulted in a strong signal with peptide 2 and a weak signal
with peptide 1 (Figure 3b). The anti-V m254 mAb, did not bind to
any of the peptides, suggesting that its epitope may be
conformational (Figure 3c). In initial studies with m254 we saw
some weak binding to peptides 36 and 42, but when we repeated
the binding studies with the human anti-V mAbs we did not see
binding to peptides 36 and 42. This might explain its weak
competition with mouse antibodies that recognize diverse epitopes
on the V-antigen (Figure 2b). The positive signals seen with the
m253 and m254 mAbs with V-antigen peptides (numbers 19, 20,
27, and 28) are nonspecific signals that are generated by the
secondary antibody (Amemiya et al. unpublished). The epitopes of
the mouse antibodies have also been determined by the peptide
binding assay (Amemiya, et al. unpublished). The data is consistent
with the competition-ELISA presented in this study.
Specific binding of human anti-F1 IgG1 to Y. pestis
To test if the human anti-F1 and anti-V IgGs bind their
respective targets on bacterial cells, we performed flow cytometry
analysis. Both the mouse anti-F1 F1m mAb and human anti-F1
m252 mAb bound specifically to Y. pestis grown at 37uC and not to
the same strain grown at 26uC. Neither did they bind to a control E.
coli strain grown at 37uC (Figure 4, bottom panel). This is consistent
with previous reports that the expression of the F1-antigen is
regulated by temperature (37uC), and it is not expressed at RT. The
human anti-V m254 mAb showed minor binding to the Y. pestis
grown at 37uC, although we do not normally see binding with the
human anti-V m253 or mouse anti-V mAbs, which included 7.3 m,
74–1 m, and 141–1 m (Amemiya, unpublished). A mouse IgG1
isotype control mAb, which did not show any binding to the whole-
cells, was included to show binding by the mouse and human anti-
F1 mAbs was antibody specific. To further confirm the bindingdata
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with the flow cytometry data, where only the mouse and human
anti-F1 mAb bound to Y. pestis whole-cells (Figure 5). Neither the
human anti-V m254 mAb (Figure 5D) nor mouse anti-V mAbs, like
7.3 m (data not shown) nor control samples (Figure 5A, nonspecific
mouse IgG1 isotype; Figure 5E, no primary mAb) showed
significant binding to Y. pestis.
Human anti-F1 and V mAbs protect synergistically
against a Y. pestis challenge in a bubonic plague model
The ability of the human anti-F1 and anti–V mAbs to passively
protect mice against a Y. pestis infection was evaluated in a bubonic
plague model. The human anti-F1 and anti-V mAbs were used
either separately or together in different combinations. When
mAbs m252 and m253 and m254 were given to mice separately
before challenge with Y. pestis CO92, only the human anti-
F1(m252) mAb showed some efficacy. The mean-time-to-death
(MTD) in the m252 mAb-treated mice was shifted to 13.0 days (1/
6 survivors) when compared with mice given normal mouse serum
(NMS), which had a MTD of 7.0 days (0/6 survivors) (Figure 6A).
Unlike m252, however, the human anti-V mAbs, m253 and m254,
did not show any significant protection [mean-time-to-death
(MTD) of 6.7 days (0/6 survivors) and 7.3 days (0/6 survivors),
respectively] when compared to the NMS -treated mice. The
mouse anti-F1 (F1m) and anti-V (7.3 m) control mAbs both
passively protected all (6/6) mice under the same challenge
conditions (MTD of 21 days). When both human anti-V mAbs
were given to mice passively (Figure 6B), no improvement in
protection after challenge was observed (MTD of 6.8 days, 0/6
survivors), which was similar to that seen with the NMS-treated
mice (MTD of 7.3 days, 0/6 survivors). However, when the
human anti-F1 m252 mAb (MTD of 11.3 days, 2/6 survivors) was
given together with the two human anti- V m253 and m254 mAbs,
a greater number of mice were passively protected (MTD 14.0, 5/
6 survivors) than when the antibodies were used separately,
suggesting a synergistic effect.
Figure 1. Characterization of the anti-F1 and anti-V antigen human antibodies. A. Anti-F1 human antibody m252 and anti-V human
antibodies m253 and m254 were expressed as Fabs, purified, and analyzed on a reducing SDS-PAGE gel. B. Specific binding by the Fabs antibody
fragments to their respective antigens in an ELISA assay. C. The three human anti-F1 and anti-V antibodies were expressed as IgG1s, purified and
analyzed on a reducing SDS-PAGE gel. D. Specific binding of the purified IgG1s to their respective antigens in an ELISA assay.
doi:10.1371/journal.pone.0013047.g001
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and a synergistic protective effect when the human m252 mAbs
was given with the human m253 and m254 mAbs in the bubonic
plague model, we wondered if there was any effect (positive or
negative) with a nonspecific human IgG1 mAb by itself or when
combined with the human anti-F1 m252 mAb in the number of
survivors in the mouse model of plague. To answer this question,
we injected five groups of mice with the following mAbs: one
group of mice with only a nonspecific human IgG1 mAb (Hu-
IgG1, 1500 mg); another group of mice with the mouse anti-F1
mAb (F1m, 500 mg); another group of mice with the human anti-
F1 mAb (m252, 500 mg). Two other groups of mice were included,
that were given either F1m (500 mg) or m252 (500 mg), with the
nonspecific Hu-IgG1 mAb (1000 mg) one day before challenge
with Y. pestis CO92 (Figure 7). All mice in the group that received
only the nonspecific Hu-IgG1 mAb died by day 8, which was
similar to the control antibody mouse groups in Figure 6A and 6B.
The same number of survivors was obtained (6/6) whether mice
were given only mouse F1m mAb or F1m combined with the
nonspecific Hu-IgG1. As we have seen previously (Figure 6A), only
1/6 mice survived in the group that received only human m252
mAb. When the human m252 mAb was combined with the
nonspecific Hu-IgG1 mAb, we obtained one more survivior (2/6)
than we obtained without the nonspecific Hu-IgG1 mAb. This
variation in the number of survivors was not different than we saw
previously (Figure 6B). In addition, the MTD was not affected by
the presence of the nonspecific Hu-IgG1 (15.8 days) when given
with the Hu-antiF1 mAb (15.8 days). These results suggest that the
nonspecific Hu-IgG1 mAb had little effect on the survival of mice
given the human m252 mAb or mouse F1m mAb.
Delaying time of delivery of human anti-plague mAbs
provided better protection against a plague challenge
One possible reason we observed less protection with the
human anti-F1 and anti-V mAbs in the mouse plague model was
that the level of the human IgGs may not have been sustained in
the mouse over time compared to the mouse IgG mAbs, We tested
this hypothesis in two separate studies. We first examined the
concentration of the human antibody in mice directly, by
measuring the level of m252 (anti-F1) and m253 (anti-V) in serum
after they were given the human mAbs by i.p. injection. Mouse
sera were collected at different time points after the initial dosing
and human IgG levels were monitored by direct ELISA. As seen in
Figure 8A, the anti-F1 m252 mAb appeared to have a half-life of
approximately 8 days, and the half-life of m253 mAb was
approximately 10 days. After 21 days, the levels of these two
human antibodies were undetectable. In contrast, the level of both
the mouse anti-F1 (F1m) and anti-V (7.3 m) mAbs may have
decreased initially like the human anti-plague mAbs, but after 21
days, the levels were still approximately 40–50% of the initial
concentration (Figure 8B). The half-live of human IgG mAbs in
mice reported here is similar to what was found in another study
where human mAbs were used against another biothreat agent
[18]. In contrast, a human IgG molecule would have an average
serum half -life of 21 days in a human [19].
Figure 2. Epitope binding analysis of human Fab by competition-ELISA. A and B, Fab anti-V m253 and m254 binding to the V-antigen were
analysed by competitions with equal amount of control IgG1, mouse anti-Burkholderia mallei (Bm), and five other mouse anti-V mAbs (7.3 m, 10–1 m,
74–1 m, 84–1 m, 141–1 m) as described in Materials and Methods, respectively. The amount of bound human Fab was then determined. C. Lack of
competition between human Fab anti-F1 fragment and mouse anti-F1(F1m) mAb. D. Competition among human antibodies. Fab m252, m253, and
m254 were mixed with equal amounts of IgG m253 and applied to an ELISA plate coated with their respective antigens. The amounts of bound Fab
were determined. PBS indicates m253 mixed with an equal volume of PBS buffer only. In all panels, NC indicates samples with no primary antibodies
added serving as secondary antibody controls.
doi:10.1371/journal.pone.0013047.g002
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mAb at different time points relative to the time of challenge. While
the original regimen provided consistently modest protection,
administration of the human m252 mAb 24 and 48 hours post-
challenge provided increasing protection with the 48 hours
schedule provided complete protection (Figure 9). Antibody
administration at even later time points was not performed since
mice began to die 3–4 days after challenge without any treatment.
However, we did evaluate the effect of a second dose of antibody at
a later time point. In this group, mice first received an initial dose of
human anti-F1 m252 mAb 24 hour before challenge as was done
with the earlier protocols. These mice then received a second dose
of the human anti-F1 m252 mAb 5 days after challenge. There was
an increase in both the number of survivors (5/6) and MTD (20
Figure 3. Epitope mapping of the human anti-F1 and anti-V antibodies by peptide binding assay. A. Each of twenty-seven peptides that
covered the full length of the F1-antigen were used to coat an ELISA plate (0.05 ml of a 25 mg/ml solution of each peptide), and binding by the
human anti-F1 m252 mAb (0.05 ml of a 10 mg/ml solution) was analyzed. The sample labeled F1 was the full-length antigen used to coat the plate as
the positive control (0.05 ml of a 2 mg/ml solution), and the sample labeled Media was the negative control with no primary antibody added. B and C.
Each of fifty-two peptides that covered the full length of the V- antigen was used to coat an ELISA plate (0.05 ml of a 25 mg/ml solution), and the
human anti-V m253 (B) and m254 (C) mAbs were used (0.05 ml of a 10 mg/ml solution), respectively, to analyze for binding. The sample labeled V was
the positive control (0.05 ml of a 2 mg/ml solution), and the sample labeled Media was the negative control without the primary antibody.
doi:10.1371/journal.pone.0013047.g003
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PLoS ONE | www.plosone.org 5 October 2010 | Volume 5 | Issue 10 | e13047Figure 4. Specific binding of the human anti-F1 IgG1 to the Y. pestis cell surface was detected by a flow cytometry assay. A mouse
anti-B mallei IgG1was used (10 mg/ml) as an isotype mAb control, and the mouse anti-F1 (F1-04-A-G1, F1m) mAbs was used (10 mg/ml) as a positive
IgG1 control. Y. pestis grown at 26uC (top panel) was used as an anti-F1 mAb negative control. E.coli grown at 37uC was used as a specificity control
for anti-F1 and anti-V IgGs.
doi:10.1371/journal.pone.0013047.g004
Figure 5. Immunofluorescence detection of human anti-F1 IgG1 mAb (m252) binding to the Y. pestis cell surface. The mouse anti-B
mallei IgG1 (panel A) was used as a nonspecific isotype control. The mouse anti-F1 mAb (F1m) (panel B) was used as a positive control. The binding
by the human anti-F1 mAb (m252) is shown in panel C. The rare binding shown with the human anti-V m254 to Y. pestis (panel D) was considered to
be the result of autofluoresence because it was seen in both phase contrast and fluorescent microscopy. In the bottom panel E, there was no primary
antibody in the reaction before the secondary antibody was added as a negative control.
doi:10.1371/journal.pone.0013047.g005
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administered 48 hour after challenge. These data suggest that the
optimum serum concentration of the human IgG1s was critically
dependent on the time of administration, and that the optimum
concentration of the human anti-plague IgG1s in turn determined
the outcome of the treatment protocol.
Discussion
Antibiotics have been at the forefront of combating bacterial
infection for decades with great success. However, the develop-
ment of new antibiotics is struggling to keep pace with the
emergence of drug resistant bacterial strains, for example as in Y.
pestis [6]. There has been an intense interest in developing
antibody-based therapies as an alternative method of treatment
[5]. Initially, antibody-based therapy was mostly limited to treating
cancer or immune disorders. However, because of a better
understanding of the pathogenesis of infectious agents, and the
advancement in the development of protective or neutralizing
antibodies, the use of antibody-based therapy against infectious
agents has become more frequent [20]. In this report we described
the first isolation of fully human mAbs against the Y. pestis
Figure 6. Human anti-F1and anti-V mAbs show synergistic protection when used together in the murine bubonic plague model. The
human and mouse anti-F1 and anti-V mAbs were given i.p. to mice 24 hrs before parenteral challenge with Y. pestis CO92, and the number of
surviving mice for each treatment group was monitored for 21 days after challenge. 6A. The following antibodies and amounts were used: normal
mouse serum (NMS, 500 mg); mouse anti-F1 (F1m, 500 mg); mouse anti-V (7.3 m, 100 mg); human anti-F1 (m252, 500 mg); human anti-V (m253 and
m254, 500 mg each). 6B. The following mAbs and amounts were used: NMS, 500 mg; F1m, 500 mg; m252, 500 mg; m253+ m254, 500 mg each; m252+
m253+ m254, 500 mg each.
doi:10.1371/journal.pone.0013047.g006
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that mouse mAbs can be effective in protecting mice against Y.
pestis ([13–15]. However, because they are mouse mAbs they are
not safe to use in their present form in humans [21]. Of particular
concern is the immune reaction against mouse primary antibody
sequences in human system. This may lead to severe adverse
effects and at the same time reduce the potential benefits. It is
highly desirable to have fully human antibodies for these reasons.
The fully human anti-F1 (m252) reported here displayed moderate
to good protection against a bubonic plague challenge with Y. pestis
CO92. On the other hand, the two anti-V mAbs (m253, m254)
when used separately did not show any efficacy, but when they
were used together with m252, the combination of the human
anti-plague mAbs resulted in better protection overall, suggesting a
synergistic effect between the antibodies. A similar effect was
reported in studies using mouse anti-F1 and anti-V mAbs in a
mouse model of plague [15]. Further in our case with the human
anti-F1 mAbs, when we gave mice the human anti-F1 mAb 1–2
days after challenge, we saw a greater protection against a plague
challenge could be achieved. This suggested that the maintenance
of serum concentration of the human mAbs in the mouse was
possibly one critical factor for better protection. Kinetic studies
revealed that indeed the serum concentration of the human
antibodies dropped further than the mouse anti-plague mAbs over
the course of the study. It is also plausible that the human anti-
plague mAbs might bind to other mouse antigens nonspecifically,
thus decreasing the amount of free circulating human anti-plague
antibody in the mouse.
Figure 7. A nonspecific human IgG1 antibody (Hu-IgG1) had little effect on the mean-time-to-death (MTD) and number of surviving
mice that received the human anti-F1 mAb. The nonspecific human IgG1mAb, and the human and mouse anti-F1 and anti-V mAbs were given
i.p. to mice 24 hrs before parenteral challenge with Y. pestis CO92, and the number of surviving mice for each treatment group was monitored for 21
days after challenge. Mouse or human mAbs and their amounts were given to the following groups of mice: nonspecific human IgG1 (Hu-IgG1,
1,500 mg); F1m (F1m, 500 mg); F1m (500 mg) + Hu-IgG1(1,000 mg); m252, 500 mg; m252 (500 mg) + Hu-IgG1 (1,000 mg).
doi:10.1371/journal.pone.0013047.g007
Figure 8. Serum concentrations of human and mouse anti-F1 and anti-V mAbs in the plague mouse model over time. The same
amount of human IgGs (500 mg) as used in the challenge studies were administered via i.p. and blood samples were collected at indicated time
points. The human IgG concentration was determined by ELISA. The data shown are averages from three mice for each IgG. A. The amount of
remaining human anti-F1 m252 and anti-V m254 in mouse serum. B. The amount of remaining mouse anti-F1 F1m and anti-V 7.3m in mouse serum.
doi:10.1371/journal.pone.0013047.g008
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antibodies is the epitopes the antibodies recognize. Although the
human anti-F1 (m252) mAb appeared to bind to the same region as
the mouse antiF1, which was at the amino-terminal end of the F1-
antigen (Amemiya et al., unpublished), we could not demonstrate
direct competition between these two antibody species. This
observation may be the result of the nature of the antibody binding
site or epitope, because several mouse mAbs isolated independently
recognized the same region or epitope on the F1-antigen, behaved
in the same manner (Amemiya et al., unpublished). It may be that
once these mAbs bound to the amino-terminal end of the F1-
antigen, they may not readily come off the protein or may dissociate
very slowly. Whether this is because the binding site involved both
linear and conformational sites is not known, but both the mouse
and human anti-F1 mAbs bound to the whole anti-F1 antigen very
well, but only weakly – moderately to the 59-peptides. Nevertheless,
the human m252 mAb was as protective as the mouse anti-F1 mAb
when the human mAb was given after challenge. It has also been
reported that a neutralizing epitope on the V-antigen was located in
a region spanning amino acids 135 to 275, and a possible minor,
secondary neutralizing epitope exists near the amino-terminal
region of the V-antigen [14]. Neither of our human anti-V
antibodies reported here competed with the mouse anti-V
antibodies efficiently. The minor competition between the human
anti-V Fab antibody and the mouse anti-V antibodies suggests that
the recognition site of the human anti-V antibodies is slightly
different or they may partially share conformational binding site.
These differences might be one reason for their inability to protect
as efficiently as the human anti-F1 m252 mAb.
Exactly how the human anti-F1 252 m mAb is able to protect
mice may be directly related to the presence of F1 antigen on the
surface of the plague organism. The F1-antigen has been reported
to be anti-phagocytic [22,23]. The ability of macrophages to take
up the plague organism is directly related to the lack of the F1-
antigen, and resistance to phagocytosis is related to the presence of
the F1-antigen. The binding of the human anti-F1 252 m mAb to
the surface of the plague bacilli or opsonization may trigger
phagocytosis of encapsulated bacilli into macrophages, thereby
allowing phagocytic cells to clear the host of the pathogen.
The exact mechanism by how the V-antigen exerts it virulence
is not completely known. There are reports showing that V-
antigen is secreted into the growth medium and the secretion is
important for virulence [24,25]. The secretion of V-antigen in the
medium has been described to be dependent on contact with the
host cell, and could also be directed into the host cell by a Yersinia
outer proteins (Yops) dependent secretion (Ysc) type III system
(TTSS) [26–28]. It also has been suggested that free V-antigen
may enter the cell by endocytosis besides being injected into the
cell by the Ysc TTSS [29]. Once inside the host-cell, we do not
know exactly what host proteins interact with the intracellular V-
antigen [29]. Nevertheless, there is some evidence that anti-V
antibodies enhance phagocytosis through possibly the Fc receptor,
and thereby block Yop delivery into the host cell, and thus
preventing Ysc dependent TTSS injection of V-antigen into the
host cell [30,31].
In this study, however, we were not able to detect binding of the
human anti-V mAbs on the surface of Y. pestis cells by flow
cytometry or fluorescent microscopy, suggesting that the V-
antigen was not on the bacterial cell surface under the conditions
used in our studies or the expression level of V-antigen was below
the level of detection. As has been discussed previously, however,
the presence of V-antigen on the surface of the cell may be
dependent on contact with the eukaryotic host cell. The highly
specific region of the neutralizing epitope (s) on the V-antigen
suggests a possible ligand-receptor interaction between the V-
antigen and a cellular factor. This indicates that perhaps the V-
antigen exerts its biological effect through mechanisms other than
mediating the TTSS pathway.
In conclusion, the human anti-plague antibodies reported here
represent perhaps the ones that are closest to practical clinical use.
They may be safer and more efficient in the human system due to
their fully human nature, and a likely longer half-life in humans.
Also, intravenous application of the antibodies in humans may be
a rapid delivery system that may augment antibiotics treatment in
plague-exposed individuals. Finally, the affinity of all three
antibodies can be further increased using readily available
techniques, may reduce the dose required for efficient protection.
The successful development of these three human anti-plague
Figure 9. Post-challenge administration of the human anti-F1 m252 mAb conferred better protection. The human anti-F1 m252 mAb
was administered before or after Y. pestis challenge, and mice were monitored for 21 days after challenge. The mouse anti-V 7.3m mAb (100 mg) was
used as a positive control mAb. Normal human serum (NHS, 500 mg), which was used as a negative control, had only 5 mice per group. The numbers
behind each antibody represent the time in days in which the antibody was administered (500 mg) to mice relative to the day of challenge (day 0).
The two numbers after the human anti-F1 m252 (21 and +5) represent two different days when the mAb (500 mg) was added to the same group of
mice relative to the day of challenge.
doi:10.1371/journal.pone.0013047.g009
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antibodies can be potentially developed using the same approach
but with restricted V-antigen subunit fragments containing the
critical neutralizing epitopes, and perhaps other virulent factors.
Materials and Methods
Bacterial strains and cultivation
The Y. pestis CO92 strain used in the challenge studies was
originally obtained from T. Quan, Centers for Disease Control
and Prevention, Fort Collins, Co. It was isolated from the sputum
of a human case of pneumonic plague [32]. The Y. pestis CO92
was grown and inoculum prepared for challenges essentially as
described previously [33]. A Y. pestis pgm- strain, which was
originally isolated from Y. pestis CO92, and used in the antibody
binding studies described below was obtained from Susan L.
Welkos (USAMRIID, Frederick, MD).
Proteins and peptides
Y. pestis purified F1,V, and F1-V [34] protein antigens were
obtained from Brad Powell (USAMRIID, Fort Detrick, Frederick,
MD). The 27-peptide array that covered the F1-antigen were 14-
to 17-mers with 11 amino acid overlaps; they were obtained from
the Biodefense and Emerging Infections Research Resources
Repository (BEI)(Manassas, VA). The 53-peptide array that
covered the V-antigen were 15- to 17-mers with 11 or 12 amino
acid overlaps and were obtained from BEI.
Mouse and human monoclonal antibodies
The anti-F1 mouse mAb F1-04-A-G1 (or mF1) was provided by
George Anderson (USAMRIID) [13], and anti-V mouse mAbs
10–1 m, 74–1 m, 84–1 m, and 141–1 m as well as the control
IgG1 mouse anti-Burkholderia mallei (Bm) antibody were obtained
from Sylvia Trevino (USAMRIID) and anti-V mouse mAb 7.3
(7.3 m) was obtained from Jim Hill (Porton Down, Wiltshire, UK)
[14] and used in competition ELISAs and as positive controls in
mouse passive protection experiments. All mice mAbs were IgG1
isotypes. The human IgG1 control mAb used in the passive
protection study was an anti-human IGFII mAb.
Selection of anti-F1 and V Fabs
Purified F1-and V-proteins were either coated directly to
Maxisorp plates (Nunc, Denmark) in PBS buffer at 4uC, overnight
for plate format panning or were biotin-labeled first with EZ-link
Sulfo-NHS-LC-Biotin (Pierce, Rockford, IL) for streptavidin-
conjugated magnetic bead format panning. The labeling was
performed according to the manufacture’s recommended proto-
col. For the plate format, approximately 10
12 Fabs displayed on
the surface of phage amplified from a large naive library [35] were
suspended in PBS with 2% dry milk and applied to wells coated
with the F1- or V- proteins. After incubating for 2 hours at room
temperature, each well was washed 5 times for the first round and
10 times for the subsequent four rounds before the phage were
rescued with TG1 cells at the exponential growth phase. For the
bead format, biotin-labeled F1- and V-antigens were first
incubated with the same amount of phage as in the plate format
in 1 ml of PBS+2% dry milk suspension at room temperature for
2 hour. Fifteen ml of Dynabeads MyOne Streptavidin T1(Invitro-
gen Dynal AS, Oslo, Norway) pre-blocked with PBS+2% dry milk
was then added to the antigen/phage mixture for one hour at
room temperature. The beads were then washed 5 times with PBS
for the first round and 10 times for the subsequent four rounds of
selection. Phage were then rescued with TG1 cells. A total of four
rounds were performed for each antigen with each format.
Monoclonal ELISA was then performed to select for positive
clones. One hundred clones were screened for each antigen from
each format. Only clones displaying an OD405.2.0 were selected
for plasmid preparation and sequencing.
Expression, purification, conversion to IgG1, and
generation of stable clones
Clones selected as described above were transformed into E.coli
strain HB2151 for expression [36]. Briefly, a single clone was
inoculated into 2YT supplemented with 100 units of ampicillin
and 0.2% glucose and incubated at 37uC with shaking. When the
OD600 reached 0.6–0.9, IPTG was added to achieve a final
concentration of 1 mM and the culture was shifted to 30uC with
shaking and incubated overnight. Cells were then collected, and
lysed with polymyxin B (Sigma, St Louis) in PBS, and mixture
subjected to Ni-NTA agarose bead (Qiagen, Hilden, Germany)
purification. For IgG1 production, the heavy and light chains of
the respective Fabs were cloned into the bi-cistronic expression
vector pDR12 kindly provided by Dennis Burton (Scripps
Research Institute, La Jolla, CA). For small scale IgG1 production,
transient transfection and expression in Freestyle HEK 293F cells
(Invitrogen, Carlsbad, CA) were used. For large scale production,
stable clones were generated using CHO-K1 (ATCC, Manassas,
VA) cells. Briefly, the heavy and light chains of the three human
anti-plague IgG1s were cloned into pDR12 vectors and transfected
into CHO-K1 cells. One day after transfection, the cells were re-
plated and subjected to selection in GMEM medium supplement-
ed with 25 mM MSX. Two weeks later, the MSX resistant clones
were amplified further. The clones were tested for the expression
of respective IgG1s and then adapted to growth in serum-free
medium HyQSFM4CHO (HyClone, Logan, UT) supplemented
with 30 mM MSX. The serum-free growth medium was then
collected and passed through a protein A-sepharose resin column
for IgG1 purification.
Characterization of the binding by the human anti-F1
and anti-V Fabs and IgGs
An ELISA assay was used to assess the binding ability of the
Fabs and IgG1s. Briefly, F1- and V-antigens were coated to a
Costar high binding 96-well plate (Corning, Corning, NY) and
incubated overnight at 4uC. The next day, the plate was blocked
with 2% dry milk in PBS before serial dilution of Fabs or IgGs
were applied to the plate. After an incubation of the plate at 37uC
for one hour, anti-His-horse radish peroxidase (HRP) for Fab
detection or anti-human-Fc-HRP (for IgG detection) in PBS+2%
dry milk was added to each plate and incubated for another hour
at 37uC. The plates were then washed four times, and the ABTS
substrate (Roche, Mannheim, Germany) was added. After
approximately 10 min at room temperature, the OD405 was
taken.
For competition studies between the mouse mAbs and human
Fabs the antigen at 2 mg/ml (F1-protein or V-antigen) was used to
coat 96-well plates (Immulon 2HB, Thermo Electron, Milford,
MA), and the plates were incubated overnight at 4uC. After
washing the plates, a blocking solution (1% bovine serum albumin
with 0.05% Tween 20 in PBS) was added to the plates, and plates
incubated for 1 hr at 37uC. The flag-labeled human Fabs, and
biotinylated-mouse mAb were allowed to bind to the antigen
simultaneously for 1 hr at 37uC. To detect the presence of the
human Fab, an anti-flag-M2-peroxidase conjugate was used, and
to detect the amount of biotinylated mouse mAb present, a
streptavidin-conjugated HRP was added for 1 hr at 37uC, before
adding a hydrogen peroxidase-3,39,5,59-tetramethylbenzidine
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temperature for 15 min and read at 450 nm.
For analysis of IgG1 binding to F1- or V-antigen peptides, the
peptides were added to the plates in 0.05 ml per well at 25 mg/ml.
and the plates incubated overnight at 4uC in Immunlon 2HB 96-
well plates. After the washing and blocking steps as described
above, binding of the human and mouse mAbs IgGs was detected
as described above. The binding of all mAbs to the peptides was
evaluated at 10 mg/ml.
Flow cytometry and immunofluorescence analysis of IgG
binding to bacterial cells
Flow cytometry was used to analyze the binding of the human
anti-F1 and anti-V antigen IgG1s to Y. pestis pgm- whole-cells. Y.
pestis pgm- was first streaked onto a sheep-blood agar plate and
grown at room temperature (RT) for 3 to 4 days until colonies
were readily visible. A single colony was picked and inoculated
into 10 ml of Heart Infusion Broth (Remel, Lenexa, KS)
containing 0.2% xylose and 2.5 mM CaCl2, and cells grown
overnight (o/n) at RT with rigorous shaking. The next day, an
aliquot of the bacteria culture was shifted to 37uC, and the other
remained at RT, and the cultures were allowed to continue for
another 3 hours before the bacteria were collected and suspended
in PBS. Ten mL of bacterial cells was mixed with 90 mLo fF c
Block solution [PBS with 1% FCS and 10 mg/ml FcBlock (BD
Bioscience)] to achieve a final density of 1610
7 cells/ml. Human
or mouse IgGs were added to the bacterial cell suspension to a
final concentration of 10 mg/ml. After incubating at 4uC for
30 min, the bacterial cells were collect by centrifugation and
suspended in 1 ml of PBS, and cells washed twice. The bacterial
cells were then suspended in the same Fc Block solution, and
secondary antibodies, which included either goat anti-mouse IgG-
FITC (Pierce, Rockford, IL) or goat anti-human IgG-FITC
(Southern Biotech, Birmingham, AL) were added to the cells at a
dilution of 1:100. After 30 min at 4uC, the cells were then washed
three times with PBS and subjected immediately to FACS analysis
using a FACSCalibur (BD Bioscience, San Diego, CA), after the
cells were fixed with 4% paraformaldehyde. For detection of
antibody binding to whole-cells by immunofluorescent microsco-
py, the growth of Y. pestis pgm- and the sample preparation for
binding by human or mouse anti-F1 or anti-V mAbs was identical
as that for the FACS analysis, except a Nikon T-2000 fluorescent
microscope (Nikon Instruments Inc., Melville, NY) was used for
detection.
Passive protection by human or mouse anti-F1 or anti-V
mAbs and Y. pestis challenge studies
Antibodies to be evaluated for their efficacy against a plague
challenge were given intraperitoneal (i.p.)(500 mg per mouse,
except when stated differently in the figure legend) to 6–10 week
old BALB/c mice 24 h before they were challenged or at time
points post-challenge as indicated in the figure legend. The
challenge dose was prepared from frozen stocks of Y. pestis CO92
that were streaked on tryptose blood agar slants and incubated at
28uC for 48 h. After the incubation period, the slants were rinsed
with 10 mM potassium phosphate buffer, pH 7.0, and cell density
adjusted to the required density with the same buffer. Mice were
given the challenge dose of LD50 ,25–40, subcutaneously in
0.2 ml, where 1 LD50 is equal to 1.9 cfu [37] and observed for at
least 21 days. Research was conducted in compliance with the
Animal Welfare Act and other federal statues and regulations
relating to animals and experiments involving animals and adheres
to principles stated in the Guide for the Care and Use of Laboratory
Animals, National Research Council, 1996. The facility where this
research was conducted is fully accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care
International. The studies involving mice were approved by the
IACUC at the U.S. Army Medical Research Institute of Infectious
Diseases, animal protocol number AP-07-040.
Half-life of human or mouse anti-F1 and anti-V mAbs
given passively to mice
An ELISA as described above was used to detect the amount of
human or mouse anti-F1 and anti-V mAbs present in mice over
time. Briefly, F1-V protein (2 mg/ml in 0.2 M carbonate buffer,
pH 9.4)) was used to coat a 96-well plate (Immulon 2HB)
overnight at 4uC before washing and blocking. Two-fold dilutions
of mouse serum taken retro-orbitally after i.p. administration of
the mAb were made in 1X PBS with 1% BSA and 0.05% tween-
20, added to plates and incubated for 1 hr at 37uC before washing.
The amount of human or mouse anti-F1 or anti-V mAb binding to
the antigens was detected by the addition of goat-anti-human or
goat-anti-mouse IgG conjugated to HRP (Southern Biotechnolo-
gy). The results from 3 mice at each time point for each mAb was
performed in triplicate and were reported as the mean of the
reciprocal of the highest dilution giving a mean OD of at least 0.1,
which is at least twice the standard deviation (SD).
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